XR9051 oral inhibitor of p-glycoprotein: XNVAY presently will start Phase I studies in healthy volunteers.

Xenova Group plc (XNVAY), Slough, U.K. Product: XR9051 oral inhibitor of p-glycoprotein Indication: Multidrug resistant cancers Status: XNVAY presently will start Phase I studies in healthy volunteers...